SCHEMBL24924342

SCHEMBL24924342

CC(C)c1cc(F)c(-c2ccc(=O)n(C)c2)cc1O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 9/20 0.40
SOS1 Q07889 1/20 0.38
CREBBP Q92793 4/20 0.36
WDR5 P61964 1/20 0.36
BMPR1B O00238 1/20 0.34
BMPR1A P36894 1/20 0.34
TGFBR1 P36897 1/20 0.34
ACVRL1 P37023 1/20 0.34
ACVR1 Q04771 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33
DPP4 P27487 1/20 0.33
DPP7 Q9UHL4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25092562 0.81 HDAC6 (0.39) CREBBPWDR5LIPGHSP90AA1HSP90AB1
SCHEMBL24924345 0.79 BRD4 (0.47) BRD4SOS1CREBBPBMPR1BBMPR1A
SCHEMBL24924346 0.75 CREBBP (0.36) CREBBPBMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL22312941 0.73 HSP90AA1 (0.50) HSP90AA1HSP90AB1
SCHEMBL25065222 0.71 NOTUM (0.38) HSP90AA1
SCHEMBL3349243 0.70 BRD4 (0.45) BRD4SOS1CREBBPADORA2AADORA2B
SCHEMBL1912411 0.69 NSD2 (0.46) BRD4SOS1CREBBPADORA2AADORA2B
SCHEMBL3349238 0.69 BRD4 (0.46) BRD4SOS1WDR5
SCHEMBL22448626 0.69 LMNA (0.39) HSP90AA1HSP90AB1ADORA2A
SCHEMBL6523541 0.68 BRD4 (0.43) BRD4SOS1CREBBPADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 BRD4 2641/4885SOS1 1364/4885CREBBP 475/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 BRD4 2653/4885SOS1 1559/4885CREBBP 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.